Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RN7SK pseudogene 64 (RN7SKP64) is classified as a *pseudogene*—a DNA sequence similar to the functional 7SK small nuclear RNA (snRNA) gene but that does not produce a functional product. Unlike the canonical 7SK snRNA, which is an evolutionary conserved, abundant small non-coding RNA important for regulating transcription elongation in metazoans via sequestration and inhibition of the P-TEFb transcription factor complex, RN7SKP64 is not known to be transcribed or, if transcribed, not functional. There is no evidence that RN7SKP64 has a biological function, or any relevance as a receptor, enzyme, transporter, signaling molecule, or therapeutic target. It is important to distinguish this pseudogene from the bona fide RN7SK gene, which encodes functional 7SK RNA with well described regulatory roles in transcription. Key Considerations: - RN7SKP64 is not a therapeutic target, and there is no evidence it interacts with drugs or is relevant to disease roles, biological functions, or mechanism of action in any established sense. - The functional 7SK snRNA is not a protein, receptor, or canonical drug target but a regulatory non-coding RNA. - Listings of RN7SKP64 in genetic databases reflect genomic annotation only; it is not a functional gene. Summary: RN7SKP64 is a pseudogene with no evidence for transcription, protein coding, or biological function, and should not be considered a molecular target for therapy or research except as a genomic marker. If seeking functional RNA, refer to "7SK small nuclear RNA" (gene symbol RN7SK), not RN7SKP64.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RN7SK pseudogene 64 (RN7SKP64).